Dr Alice U Lee, Department of Gastroenterology and Hepatology, Concord Hospital, Sydney, NSW 2139, Australia. Email: [email protected]Search for more papers by this author

David Van Der Poorten,

David Van Der Poorten

Department of Gastroenterology and Hepatology, Concord Hospital, and

Both authors contributed equally to this work.

Search for more papers by this author

Emilia Prakoso,

Emilia Prakoso

AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

Both authors contributed equally to this work.

Search for more papers by this author

Teh-Liane Khoo,

Teh-Liane Khoo

Department of Gastroenterology and Hepatology, Concord Hospital, and

Search for more papers by this author

Meng C Ngu,

Meng C Ngu

Department of Gastroenterology and Hepatology, Concord Hospital, and

Search for more papers by this author

Geoffrey W McCaughan,

Geoffrey W McCaughan

AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

Search for more papers by this author

Simone I Strasser,

Simone I Strasser

AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

Search for more papers by this author

Alice U Lee,

Corresponding Author

Alice U Lee

Department of Gastroenterology and Hepatology, Concord Hospital, and

Dr Alice U Lee, Department of Gastroenterology and Hepatology, Concord Hospital, Sydney, NSW 2139, Australia. Email: [email protected]Search for more papers by this author

First published: 15 August 2007

https://doi.org/10.1111/j.1440-1746.2007.05093.x

Citations: 12

Share a link

Email
Wechat
Bluesky

Abstract

Background and Aim: The outcomes of lamivudine-resistant chronic hepatitis B patients treated with long-term adefovir dipivoxil have not been well described. This study aims to characterize the virological and biochemical response and to determine factors that may influence the development of resistance to adefovir.

Methods: A retrospective review was conducted on all patients with lamivudine-resistant chronic hepatitis B treated with adefovir for a minimum of 6 months at two tertiary referral centers.

Results: Data on 161 patients were analyzed. Seventy-two percent achieved an initial virological response with eventual normalization of alanine aminotransferase in only 67% of patients. Seventeen patients developed adefovir resistance with cumulative resistance rates of 3.2%, 8.8%, and 18% at 12, 24, and 36 months, respectively. Twelve (71%) of these patients had a biochemical breakthrough, with one death from fulminant hepatic failure. The median duration of lamivudine crossover was 1 month in adefovir-resistant patients, compared with 12 months for the remainder of the cohort (P < 0.01). Longer crossover therapy reduced the adefovir resistance rate, but did not eliminate it. No adefovir resistance is reported in those who were continued on long-term combination lamivudine–adefovir without a period of adefovir monotherapy.

Conclusions: Combination lamivudine–adefovir therapy protected against the emergence of adefovir resistance.

References

1 Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 2003; 36: 687–96.
10.1086/368083
CAS PubMed Web of Science® Google Scholar
2 Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B [see comment]. Gastroenterology 2003; 125: 1714–22.
10.1053/j.gastro.2003.09.033
CAS PubMed Web of Science® Google Scholar
3 Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81–90.
10.1053/j.gastro.2003.10.050
CAS PubMed Web of Science® Google Scholar
4 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 2003; 348: 800–7.
10.1056/NEJMoa021812
CAS PubMed Web of Science® Google Scholar
5 Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B [see comment]. N. Engl. J. Med. 2003; 348: 808–16.
10.1056/NEJMoa020681
CAS PubMed Web of Science® Google Scholar
6 Westland CE, Yang H, Delaney W et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38: 96–103.
10.1053/jhep.2003.50288
CAS PubMed Web of Science® Google Scholar
7 Yang H, Westland CE, Delaney W et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36: 464–73.
10.1053/jhep.2002.34740
CAS PubMed Web of Science® Google Scholar
8 Locarnini S, Qi X, Arterburn S et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [Abstract]. J. Hepatol. 2005; 42: A32.
Google Scholar
9 Craxi A, Antonucci G, Camma C. Treatment options in HBV. J. Hepatol. 2006; 44: S77–83.
10.1016/j.jhep.2005.11.018
CAS PubMed Web of Science® Google Scholar
10 Lok ASF, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857–61.
10.1002/hep.20110
PubMed Web of Science® Google Scholar
11 Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 2006; 44: 283–90.
10.1016/j.jhep.2005.10.018
CAS PubMed Web of Science® Google Scholar
12 Lampertico P, Marzano A, Levrero M et al. A multicentre Italian study of rescue adefovir dipivoxil in lamivudine resistant patients; a 2-year analysis of 650 patients [Abstract]. J. Hepatol. 2006; 44: S51.
10.1016/S0168-8278(06)80117-0
Web of Science® Google Scholar
13 Lee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385–91.
10.1002/hep.21189
CAS PubMed Web of Science® Google Scholar
14 Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med. 2000; 342: 1266–71.
10.1056/NEJM200004273421707
CAS PubMed Web of Science® Google Scholar
15 Snow A, Qi X, Zhu Y et al. Combination of adefovir (ADV) and lamivudine (LAM) prevented emergence of adefovir resistance mutations in chronic hepatitis B patients with lamivudine-resistant HBV [Abstract]. Gastroenterology 2005; 128 (Suppl. 2): A745.
Web of Science® Google Scholar
16 Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin. Liver Dis. 2006; 26: 162–70.
10.1055/s-2006-939758
CAS PubMed Web of Science® Google Scholar
17 Martin P. Role of combination therapy in chronic hepatitis B virus infection. Medsc. Gastroenterol. (Serial online) 2006; 8. [Cited 16 May 2007.] Available from URL: http://www.medscape.com/viewarticle/536558
Google Scholar
18 Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307–13.
10.1002/hep.21534
CAS PubMed Web of Science® Google Scholar
19 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2673–81.
10.1056/NEJMoa042957
CAS PubMed Web of Science® Google Scholar
20 Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J. Viral. Hepat. 2006; 13: 250–5.
10.1111/j.1365-2893.2005.00687.x
CAS PubMed Web of Science® Google Scholar
21 Peters MG, Hann Hw H, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B [see comment]. Gastroenterology 2004; 126: 91–101.
10.1053/j.gastro.2003.10.051
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume22, Issue9

September 2007

Pages 1500-1505

Combination adefovir–lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Combination adefovir–lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B

Abstract

References

Citing Literature

References

Related

Information